Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
NCT ID NCT02769962
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prostate cancer that has come back or stopped responding to standard treatments. The goal is to find the safest dose and see whether the combination can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EP0057 (nanoparticle camptothecin) and olaparib
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat small cell lung, bladder, or prostate cancers.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drugs may cause serious side effects like low blood counts or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States